Buerger's disease primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

An effective measure for the primary prevention of Buerger’s disease is smoking cessation. This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of bupropion and varenicline for preventing cravings is permissible.

Primary Prevention

An effective measure for the primary prevention of Buerger’s disease is smoking cessation.^[1]^[2]^[3]
This should include complete abstinence without the use of nicotine-containing anti-smoking aids, such as transdermal patches and gum. However, the use of bupropion and varenicline for preventing cravings is permissible.

References

↑ Olin JW (September 2000). “Thromboangiitis obliterans (Buerger’s disease)”. N. Engl. J. Med. 343 (12): 864–9. doi:10.1056/NEJM200009213431207. PMID 10995867.
↑ Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR (November 1990). “The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease)”. Circulation. 82 (5 Suppl): IV3–8. PMID 2225420.
↑ Ohta T, Ishioashi H, Hosaka M, Sugimoto I (January 2004). “Clinical and social consequences of Buerger disease”. J. Vasc. Surg. 39 (1): 176–80. doi:10.1016/j.jvs.2003.08.006. PMID 14718836.

Template:WH Template:WS

[pmid10995867-1] Olin JW (September 2000). “Thromboangiitis obliterans (Buerger’s disease)”. N. Engl. J. Med. 343 (12): 864–9. doi:10.1056/NEJM200009213431207. PMID 10995867.

[pmid2225420-2] Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR (November 1990). “The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease)”. Circulation. 82 (5 Suppl): IV3–8. PMID 2225420.

[pmid14718836-3] Ohta T, Ishioashi H, Hosaka M, Sugimoto I (January 2004). “Clinical and social consequences of Buerger disease”. J. Vasc. Surg. 39 (1): 176–80. doi:10.1016/j.jvs.2003.08.006. PMID 14718836.

[1]

[2]

[3]